Flavin adenine dinucleotide (FAD) is a coenzyme and acts as a redox cofactor in metabolic process. Owing to such problems as poor electron transfer properties, unfavorable adsorption, and lack of stability on rigid electrodes, the bio-electrochemical applications of FAD have been limited. Herein, a novel fabrication method was developed for the immobilization process using 2D MXene (Ti₃C₂T_x), which enhanced the redox property of FAD and improved the electro-catalytic reduction of hydrogen peroxide (H₂O₂) in neutral medium. The FAD-immobilized Ti₃C₂T_x electrode (FAD/Ti₃C₂T_x) was studied by UV-Visible and Raman spectroscopies, which confirmed the successful adsorption of FAD on the Ti₃C₂T_x surface. The surface morphology and the elemental composition of Ti₃C₂T_x were investigated by high resolution transmission electron microscopy and the energy dispersive X-ray analysis. The redox property of the FAD/Ti₃C₂T_x modified glassy carbon electrode (FAD/Ti₃C₂T_x/GCE) was highly dependent on pH and exhibited a stable redox peak at −0.455 V in neutral medium. Higher amounts of FAD molecules were loaded onto the 2D MXene (Ti₃C₂T_x)-modified electrode, which was two times higher than the values in the reported work, and the surface coverage (ᴦ_FAD) was 0.8 × 10⁻¹⁰ mol/cm². The FAD/Ti₃C₂T_x modified sensor showed the electrocatalytic reduction of H₂O₂ at −0.47 V, which was 130 mV lower than the bare electrode. The FAD/Ti₃C₂T_x/GCE sensor showed a linear detection of H₂O₂ from 5 nM to 2 µM. The optimization of FAD deposition, amount of Ti₃C₂T_x loading, effect of pH and the interference study with common biochemicals such as glucose, lactose, dopamine (DA), potassium chloride (KCl), ascorbic acid (AA), amino acids, uric acid (UA), oxalic acid (OA), sodium chloride (NaCl) and acetaminophen (PA) have been carried out. The FAD/Ti₃C₂T_x/GCE showed high selectivity and reproducibility. Finally, the FAD/Ti₃C₂T_x modified electrode was successfully applied to detect H₂O₂ in ovarian cancer cell lines.

Graphene and its related nanocomposites have garnered significant interest due to their distinct physiochemical and biological properties. In this study, reduced graphene oxide–silver hybrid nanostructures were synthesized for applications in biomedical nanotechnology, particularly in targeting cancer stem cells (CSCs). A range of analytical techniques, such as X-ray diffraction (XRD), Raman spectroscopy, Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and UV–visible absorption spectroscopy (UV–VIS), were employed to characterize graphene oxide (GO), reduced graphene oxide (rGO)–silver nanoparticles (AgNPs), and their composite structures. The GO-rGO-AgNPs exhibited potent anticancer properties as evidenced by cell culture assays, spheroid formation assay, and quantitative RT-PCR analysis. Treatment of breast cancer cells (MCF-7) with GO, rGO, and AgNPs significantly reduced cell proliferation and mammosphere formation. Furthermore, these treatments downregulated the expression of marker genes associated with CSCs in MCF-7 cells. Among the tested materials, rGO-AgNP, sodium citrate-mediated GO-AgNP, and rGO-AgNP nanocomposites demonstrated superior inhibitory effects on cell survival compared to GO alone. These findings suggest that these nanocomposites hold promise as effective and non-toxic therapeutic agents for targeting cancer cells and CSCs, thereby offering a novel approach to cancer treatment.

Graphene and its related nanocomposites have garnered significant interest due to their distinct physiochemical and biological properties. In this study, reduced graphene-oxide-silver hybrid nanostructures were synthesized for applications in biomedical nanotechnology, particularly in targeting cancer stem cells (CSCs). A range of analytical techniques, such as X-ray diffraction (XRD), Raman spectroscopy, Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and UV-visible absorption spectroscopy (UV-VIS), were employed to characterize graphene oxide (GO), reduced graphene oxide (rGO)-silver nanoparticles (AgNPs) and their composite structures. The GO-rGO-AgNPs exhibited potent anticancer properties as evidenced by cell culture assays, spheroid formation assay, and quantitative RT-PCR analysis. Treatment of breast cancer cells (MCF-7) with GO, rGO, and AgNPs significantly reduced cell proliferation and mammosphere formation. Furthermore, these treatments downregulated the expression of marker genes associated with CSCs in MCF-7 cells. Among the tested materials, rGO-AgNP, sodium citrate- mediated GO-AgNP, and rGO-AgNP nanocomposites demonstrated superior inhibitory effects on cell survival compared to GO alone. These findings suggest that these nanocomposites hold promise as effective and non-toxic therapeutic agents for targeting cancer cells and CSCs, thereby offering a novel approach to cancer treatment.

Cancer prevention through dietary intervention utilizing bioactive natural compounds has garnered significant attention due to the therapeutic limitations of conventional cancer treatments. These plant-derived active compounds, including polyphenols, terpenoids, organosulfur compounds, bioactive peptides, and alkaloids, possess potent anticancer properties. This systemic review addresses a critical gap in the scientific literature by elucidating the precise multitargeted oncogenic regulatory mechanisms of these molecules. A comprehensive methodology was employed, involving a systematic literature search across major electronic databases (including PubMed, Web of Science, Embase, and SCOPUS) to identify relevant original peer-reviewed studies. The evidence gathered demonstrates that these active compounds deliver significant health benefits and protect cells by modulating crucial molecular targets involved in cell cycle regulation, apoptosis, oncogenic signaling, epigenetic control, angiogenesis, oxidative stress, and inflammation. Specifically, they operate via multi-targeted cascades, such as inhibiting the PI3K/Akt, NF-κB, and STAT3 pathways. To provide a clear structural overview, these active compounds are categorized comprehensively based on their botanical and structural origins, including spices, fruits, and rhizomes. However, despite their promising bioactivities, these compounds have not yet been fully translated into clinical therapy due to challenges such as low bioavailability, rapid metabolism, limited systematic exposure, and a lack of convincing evidence from large-scale clinical trials. Although most current evidence remains rooted in in vitro and experimental animal models, clinical validation through high-quality trials is still required. Ultimately, this review underscores the potential of these active compounds and highlights how advances in formulation and nano delivery strategies offer promising solutions for effective cancer prevention.